CN Bio, a leading Organ-on-a-chip (OOC) company de-risking drug discovery and development pipelines by enabling earlier, more ...
ORIC-259 is a potential first-in-class small molecule mRNA degrader targeting CIP2A, a previously undruggable target. Cancer ...
Dr. Meltzer joins Avilar as the company advances its lead ATAC program toward the clinic. The program is an ATAC designed to ...
Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced an oral presentation will be featured at the upcoming ...
The incidence of melanoma is steadily rising, with annual cases projected to increase by more than 50% between 2020 and 2040.
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient ou ...
Nature Aging findings point to a key role for chaperone-mediated autophagy and suggest ways to clear cells that damage the ...
Motivista is a prescription digital therapeutic indicated for the treatment of negative symptoms of schizophrenia as an ...
WO 2026/178627 covers methods, uses and compositions pairing Streptococcus salivarius SALI-10 with sorbitol, creating a ...
FDA clearance of its Investigational New Drug (IND) application for MC001, the Company's first-in-class dimeric ...
Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral ...
UPPSALA, SE / ACCESS Newswire / October 5, 2026 / Senzime (STO:SEZI)(OTCQX:SNZZF) - "We reaffirm our target of reaching ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results